The process of neurodegeneration is characterized by an accumulation of proteins in aggregated form. This aggregation suggests impairment of protein production or turnover. Hallmarks of Alzheimer’s disease (AD), Parkinson’s disease (PD) and frontotemporal dementia (FTD) include accumulation of these protein aggregates. Multiple factors contribute to the accumulation of aggregated proteins in these diseases including genetic mutations, dysfunctional proteostasis, and other disease related risk factors. The goal of this assay is to characterize changes in lysosomal function across a broad set of samples and disease types utilizing dysregulated proteins identified through discovery proteomics, genomics, and metabolomics/lipidomics. In this assay we use mass spectrometry (MS) based relative quantitation to determine changes in the concentrations of specific proteins over time or treatment. The multiplexed panel measures 77 peptides from 33 proteins involved in the lysosomal biology pathway.

For In Vitro Diagnostic Use.